Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Relapsing NMOSD
NCT02893111Phase 2Completed
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Annual Relapse Rate at 12 months. Started Dec 2015; status: completed.
02
Drugs
bortezomib
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT02893111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893111.